31 Stocks Moving In Monday's Mid-Day Session

Gainers

• Sienna Biopharmaceuticals Inc SNNA climbed 54% to $0.1747 on seemingly no company-specific news.
• Dova Pharmaceuticals, Inc. DOVA shares climbed 38.9% to $28.03 in reaction to a buyout deal. Dova said Monday it has entered into an agreement to be bought by Swedish Orphan Biovitrum, or SOBI, for $27.50 per share in cash, along with one non-tradeable contingent value right, or CVR, that entitles Dova shareholders to receive an additional $1.50 per share in cash upon regulatory approval of Doptelet.
• Thor Industries, Inc. THO gained 16.9% to $57.17 after the company reported better-than-expected Q4 EPS results.
• Seattle Genetics, Inc. SGEN shares rose 12.4% to $85.37 after Piper Jaffray maintained an Overweight rating on the stock and raised the price target from $75 to $95. Piper Jaffray raised the price target after Seattle Genetics presented compelling initial data from the EV-103 study, which compares favorably to the current standard of care. It also sees the potential for further upside from additional UBS opportunities.
• GTT Communications, Inc. GTT gained 10.1% to $8.59 as a potential rebound after the stock fell roughly 20% since last Thursday when the stock could not break the $10 resistance level.
• Patrick Industries, Inc. PATK climbed 8.7% to $42.35. Patrick Industries completed the acquisition of G.G. Schmitt & Sons, Inc.
• Cerus Corporation CERS gained 7.5% to $5.22.
• REGENXBIO Inc. RGNX climbed 6.7% to $35.58.
• Bed Bath & Beyond Inc. BBBY rose 6% to $10.48. Wedbush upgraded Bed Bath & Beyond from Neutral to Outperform and raised the price target from $14 to $16.
• GreenSky, Inc. GSKY gained 5.7% to $6.78.

Check out these big penny stock gainers and losers

Losers

• Ocugen Inc OCGN shares tumbled 77.5% to $2.1852. Ocugen announced the completion of its merger with Histogenics Corporation. Ocugen and CanSinoBIO reported a strategic partnership for gene therapy co-development and manufacturing.
• G1 Therapeutics, Inc. GTHX fell 21.1% to $26.79. G1 Therapeutics presented updated data at ESMO 2019 from randomized Phase 2 trial of trilaciclib in combination with chemotherapy in metastatic triple-negative breast cancer demonstrating significant improvement in overall survival at ESMO 2019.
• Adamas Pharmaceuticals, Inc. ADMS dipped 19.1% to $5.39. Bank of America downgraded Adamas Pharmaceuticals from Neutral to Underperform.
• BENITEC BIOPHAR/S ADR BNTC dropped 18.9% to $0.6810 after reporting a $2.25 million registered direct offering.
• Calithera Biosciences, Inc. CALA fell 16.9% to $2.70. Calithera Biosciences announced data from randomized Phase 2 ENTRATA study demonstrate telaglenastat with everolimus improves progression-free survival in renal cell carcinoma at ESMO 2019.
• Globus Maritime Ltd GLBS shares fell 16.4% to $1.94. Globus Maritime reported a Q2 loss of $0.74 per share, versus a year-ago loss of $0.29 per share. Its sales slipped to $3.4 million from $4.194 million.
• Lexicon Pharmaceuticals, Inc. LXRX dropped 12.8% to $2.9959, potentially following a bearish blog post alleging the company does not have enough cash to finish ongoing trials.
• Immunomedics, Inc. IMMU shares fell 12.7% to $12.51 after interim data from the company's phase 2 study of Sacituzumab Govitecan showed a 29 percent response rate.
• Arcus Biosciences, Inc. RCUS shares declined 12.5% to $8.91.
• SunCoke Energy, Inc. SXC dipped 11% to $5.61.
• Cal-Maine Foods, Inc. CALM fell 10% to $40.86 after the company reported worse-than-expected Q1 EPS and sales results.
• ImmunoGen, Inc. IMGN dipped 9.6% to $2.46 after the company presented data from its unsuccessful FORWARD I study of mirvetuximab. Piper Jaffray analysts noted a change in methodology may have led to the enrollment of patients who did not meet intended threshold.
• Precipio, Inc. PRPO dropped 9.3% to $2.55.
• InMode Ltd. INMD shares declined 8.9% to $20.27 as traders potentially took profits after the stock increased roughly 100% since its recent IPO in early August.
• Precision BioSciences, Inc. DTIL dropped 8.8% to $8.10. Precision BioSciences, named Nicholas Riddle, MB, BChir (MD), PhD, as Vice President, Financial Strategy and Investor Relations.
• NextCure, Inc. NXTC dropped 8.7% to $29.90.
• Teekay LNG Partners L.P. TGP shares fell 8% to $13.92. Teekay Companies will postpone its investor day originally scheduled on Oct 2 to focus on Teekay LNG.
• Abeona Therapeutics Inc. ABEO dropped 7.3% to $2.28.
• Teekay Corporation TK fell 6.2% to $3.9699. Teekay Companies will postpone its investor day originally scheduled on Oct 2 to focus on Teekay LNG.
• Mirati Therapeutics, Inc. MRTX fell 5.3% to $79.99.
• Coeur Mining, Inc. CDE fell 5.1% to $4.9450.